Quantcast

Latest Clostridium difficile Stories

2014-09-17 12:27:55

Rebiotix microbiota-based drug candidate used to assess a non-antibiotic approach to an urgent public health threat ROSEVILLE, Minn., Sept. 17, 2014 /PRNewswire/ -- Rebiotix Inc. announced this morning that results of the Phase 2 study of the company's lead product candidate, RBX2660 (microbiota suspension) will be presented in two posters and a podium presentation during the IDWeek 2014 conference in Philadelphia from October 8-12. PUNCH CD study results will be presented during the poster...

2014-09-17 04:21:26

GLASGOW, Scotland, September 17, 2014 /PRNewswire/ -- First antibacterial with a new mode of action from a truly novel class of anti-infective in over a decade MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has secured GBP4.0m ($6.4m) to advance the development of its lead antibacterial, MGB-BP-3, against a range of Gram-positive infections including Clostridium...

2014-09-16 12:30:33

-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept. 16, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company's Investor Day in New York which highlighted its irritable bowel syndrome (IBS) program, including...

2014-09-11 08:27:38

-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT -- ROCKVILLE, Md., Sept. 11, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host a an investor conference call on Friday, September 12, 2014, at 9:15 a.m. EDT. The conference call will highlight...

2014-09-10 12:29:04

-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board -- ROCKVILLE, Md., Sept. 10, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that its Investor Day to highlight...

2014-09-08 16:25:18

Phase I/II study also demonstrated SER-109 restoration of a diverse, healthy microbiome CAMBRIDGE, Mass., Sept. 8, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced final data for its single-arm, open-label clinical trial of SER-109, its first-in-field, oral microbiome therapeutic. SER-109, a mixture of bacterial spores, is designed for the treatment of recurrent...

2014-09-08 08:29:12

-- SYN-005 Neutralizing Antibody Combination Protects Against Pertussis in Murine and Non-Human Primate Models -- ROCKVILLE, Md., Sept. 8, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that data from its novel SYN-005 program for the treatment of Pertussis were highlighted in an oral presentation...

2014-09-07 08:20:25

ROCKVILLE, Md., Sept. 7, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today preclinical data that further validate the Company's novel approach to preventing Clostridium difficile (C. difficile). The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it...

2014-09-03 08:32:42

ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 16(th) Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday,...

Research Sniffs Out Smell Of Disease In Feces
2014-09-02 03:10:38

University of Leicester A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria C. diff, that causes diarrhea, temperature and stomach cramps, has been developed by a team at the University of Leicester. Using a mass spectrometer, the research team has demonstrated that it is possible to identify the unique 'smell' of C. diff which would lead to rapid diagnosis of the condition. What is more, the Leicester team say it could be possible to identify different...


Latest Clostridium difficile Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »
Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'